Trials / Withdrawn
WithdrawnNCT05564338
Efficacy and Safety of Sitravatinib Plus Tislelizumab or Placebo Plus Tislelizumab Versus Placebo as Adjuvant Treatment in Participants With Hepatocellular Carcinoma
A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Compare the Efficacy and Safety of Sitravatinib Plus Tislelizumab or Placebo Plus Tislelizumab Versus Placebo as Adjuvant Treatment in Patients With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Surgical Resection
- Status
- Withdrawn
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- BeiGene · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to compare the efficacy and safety of sitravatinib plus tislelizumab or placebo plus tislelizumab versus placebo. The study will also compare the recurrence-free survival (RFS) in participants with hepatocellular carcinoma (HCC) who are at high risk of recurrence after surgical resection.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sitravatinib | Administered orally |
| DRUG | Tislelizumab | Administered intravenously |
| DRUG | sitravatinib-matching placebo | administered orally |
| DRUG | tislelizumab-matching placebo | administered intravenously |
Timeline
- Start date
- 2023-06-30
- Primary completion
- 2027-04-30
- Completion
- 2028-04-30
- First posted
- 2022-10-03
- Last updated
- 2023-06-07
Source: ClinicalTrials.gov record NCT05564338. Inclusion in this directory is not an endorsement.